Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Niflumic acid
Cat. No.:
0225LY-0541
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Add to basket
Product Overview
Description:
Niflumic acid serves as a calcium-activated chloride channel blocker and is utilized as an anti-inflammatory and analgesic medication specifically for treating rheumatoid arthritis.
Synonym:
Nifluril; Forenol; Landruma; 4394-00-7; 2-{[3-(Trifluoromethyl)phenyl]amino}pyridine-3-carboxylic acid; 2-(3-(Trifluoromethyl)anilino)nicotinic acid; 2-[3-(Trifluoromethyl)anilino]pyridine-3-carboxylic acid
CAS No.:
4394-00-7
Compound CID:
4488
Formula:
C13H9F3N2O2
Formula Weight:
282.22
Specification
Relative Density:
1.3935 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Niflumic acid can be used in ion channel research to investigate its activity as a chloride channel blocker and COX-2 inhibitor.
Library Information
Target:
Chloride channel; Phospholipase; COX; MCT; UGT
Receptor:
Chloride channel; Chloride channel protein ClC-Ka; COX; Monocarboxylate transporter; PLA2; UGT
Pathways:
Immunology/Inflammation; Membrane transporter/Ion channel; Metabolism; Neuronal signaling
Plate Number:
AOCL-8
Plate Location:
a5
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
60 mg/mL; 212.6 mM
Water Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
Ethanol Max Solubility:
<1 mg/mL
